As of September 30, 2025, unrestricted cash and cash equivalents and investments in marketable debt securities totaled $133.6 million. The Company expects its cash, cash equivalents, and investments in marketable debt securities will be sufficient to fund operations into mid-2027.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics, Inc. (TARA) Q3 Earnings Cheat Sheet
- Protara Therapeutics Advances Phase 2 Study for Bladder Cancer Treatment
- Protara Therapeutics’ Choline Chloride Study: A Potential Game-Changer for Intestinal Failure Treatment
- Protara Therapeutics’ TARA-002 Study: A Potential Game-Changer for Lymphatic Malformations
- Optimistic Outlook for Protara Therapeutics: Buy Rating Driven by Promising TARA-002 Developments and Strategic Opportunities